INmune Bio (INMB) Set to Announce Quarterly Earnings on Thursday

INmune Bio (NASDAQ:INMB) is expected to post its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of ($0.1467) per share and revenue of $1.88 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.16.

INmune Bio Stock Performance

INMB stock opened at $1.61 on Thursday. The stock’s fifty day simple moving average is $2.09 and its 200-day simple moving average is $1.74. INmune Bio has a 52-week low of $1.09 and a 52-week high of $2.60.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on INMB shares. Weiss Ratings raised INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 19th. Wall Street Zen upgraded INmune Bio from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

About INmune Bio

INmune Bio, Inc is a clinical-stage biotechnology company developing immunotherapies that target the innate immune system. The company’s research focuses on addressing chronic inflammation and improving immune responses in neurological disorders and cancer.

Its lead product candidate, XPro, is an investigational selective inhibitor of soluble tumor necrosis factor (TNF), an inflammatory signaling protein. INmune Bio is evaluating XPro in conditions associated with neuroinflammation, including Alzheimer’s disease and depression-related disorders.